Trial Profile

A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (eVOLVE-Meso)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 07 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Pemetrexed (Primary) ; Volrustomig (Primary) ; Cisplatin; Ipilimumab; Nivolumab
Indications Mesothelioma
Focus Registrational; Therapeutic Use
Acronyms eVOLVE-Meso
Sponsors AstraZeneca

11 Jun 2025 Timeframe of primary endpoint change from up to approximately 52 months to 61 months
11 Jun 2025 Planned number of patients changed from 600 to 825.
04 Dec 2023 Planned End Date changed from 3 Apr 2028 to 13 Mar 2028.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com